Merck’s Bridion Could Face Generic Pressure from Hikma Ahead of Patent Expiry Date

Merck in an SEC filing disclosed on Monday that Hikma Pharmaceuticals U.S. is seeking the FDA’s approval for its generic version of the muscle relaxant reversal injection Bridion (sugammadex) prior to the drug’s patent expiration.